Top Markets
Coin of the day
Alimera Sciences, Inc. Alimera Sciences, Inc.

Alimera Sciences, Inc.

ALIM
Hisse Senetlerindeki Sıralama #26675
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and... Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Hisse Fiyatı
$5.54
Son senkronizasyon: 2024-09-18
Piyasa Değeri
$38.76M
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret Alimera Sciences, Inc. (ALIM)

Kategori

Alimera Sciences, Inc. (ALIM) için kazanç
Jun 2024 itibarıyla kazanç TTM: $-14.71M
Alimera Sciences, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $-14.71M'dir. 2022 yılında şirket $-18.08M kazanç elde etti, bu 2021 yılındaki $-3.93M kazanca göre önceki yıla göre azalma. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Alimera Sciences, Inc. için kazanç geçmişi 2006 - 2026
Her yılın sonundaki kazanç
Yıl Kazanç Değiştir
2026 (TTM) $-14.71M -26.61%
2023 $-20.05M 10.89%
2022 $-18.08M 359.56%
2021 $-3.93M -27.24%
2020 $-5.41M -47.13%
2019 $-10.23M -37.17%
2018 $-16.28M -25.47%
2017 $-21.84M -33.83%
2016 $-33.00M 8.15%
2015 $-30.52M -14.61%
2014 $-35.74M -22.70%
2013 $-46.23M 134.12%
2012 $-19.75M -12.30%
2011 $-22.52M 32.74%
2010 $-16.96M -59.95%
2009 $-42.36M -30.03%
2008 $-60.54M 383.70%
2007 $-12.52M 20.64%
2006 $-10.37M 0.00%
Benzer şirketler veya rakipler için kazanç